Zealand Pharma A/S was founded in and is a biotechnology company focused on the discovery, design and development of innovative peptide based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim.
Quote | Zealand Pharma A/S Ord (OTCMKTS:ZLDPF)
Last: | $86.08 |
---|---|
Change Percent: | -6.13% |
Open: | $85.82 |
Close: | $86.08 |
High: | $86.08 |
Low: | $85.82 |
Volume: | 1,191 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | Zealand Pharma A/S Ord (OTCMKTS:ZLDPF)
2024-04-19 06:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
2024-04-10 12:30:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We believe internation...
Message Board Posts | Zealand Pharma A/S Ord (OTCMKTS:ZLDPF)
Subject | By | Source | When |
---|---|---|---|
PR Release - FDA approval - Type II Diabetes. | Trading2retire | investorshub | 11/22/2016 2:29:27 AM |
$ZLDPF recent news/filings | stocktrademan | investorshub | 09/16/2015 3:49:35 PM |
$ZLDPF recent news/filings | stocktrademan | investorshub | 06/11/2015 7:14:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Press release – No. 3 / 2023 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the d...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a solid financial position Positive results achieved for petrelintide in 6-week Phas...